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Abstract: Milk-based media such as the Fed State Simulated Gastric Fluid (FeSSGF) are 19 
commonly used in order to simulate the in vivo properties of the fed state stomach. Due to the 20 
lack of a specific guideline for standardised sample clean-up in these media, the aim of the 21 
current study was to develop an optimum protocol for the extraction and quantification of drugs 22 
from the fed state gastric medium based on the APIs’ physicochemical properties (lipophilicity, 23 
ionisation, aqueous solubility and protein binding). Two different extraction techniques, 24 
protein precipitation (PP) and solid phase extraction (SPE) were assessed. A pilot study in six 25 
model drugs was performed, with tests using seven different protein precipitation reagents at 26 
four different medium:reagent ratios and two drug concentrations as well as different solid 27 
phase extraction cartridges and elution protocols. % recovery was analysed using partial least 28 
squares (PLS) regression so as to determine the physicochemical parameters affecting the drug 29 
percentage recovered. For protein precipitation protocols, drug concentration, selection of 30 
protein precipitation reagent and ratio added to the medium significantly affected drug % 31 
recovery from FeSSGF (p < 0.05). The same applied for the selection of elution solvent and 32 
cartridge type for solid phase extraction. Optimum protocols using MeOH, ΑCN and 10% w/v 33 
TCA at a 1:2 FeSSGF:reagent ratio were effective to a larger group of drugs of a wide range 34 
of lipophilicity and ionisation, with ΑCN being the most effective in the whole range of log P 35 
values (-0.56-8.81). Solid phase extraction was proven to be effective for compounds of poor 36 
to moderate lipophilicity (log P < 4), with extremely hydrophobic compounds demonstrating 37 
lower % recovery values (down to 10% recovery). PLS demonstrated that only for 10% w/v 38 
TCA (protein precipitation) and HLB (solid phase extraction) can the effect of key drug 39 
physicochemical properties on the final amount of drug recovered be accurately predicted. 40 
Keywords: Fed state; Protein precipitation; Solid phase extraction; Biorelevant media; Drug 41 
analysis; Physicochemical properties 42 
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Abbreviations 44 
ΑCN:acetonitrile, API:active pharmaceutical ingredient, BA/BE:Bioavailability/bioequivalence, CV:coefficient 45 
of variation, EtOH:ethanol, FeSSGF:Fed state simulated gastric fluid, GF/D:glass microfiber, HLB:hydrophilic-46 
lipophilic balance, log aq sol:logarithm of drug aqueous solubility in mg/mL, LOQ:limit of quantification, 47 
MeOH:methanol, MLR:multiple linear regression, PLS:partial least squares, PP:protein precipitation, prot b 48 
fr:drug protein bound fraction in serum proteins, RC:regenerated cellulose, SPE:solid phase extraction, 49 
PLS:partial least squares, TCA:trichloroacetic acid, TFA:trifluoroacetic acid, union fr:drug unionised fraction 50 
at pH = 5 51 
 52 
Drug abbreviations: ATE:atenolol, ATORV:atorvastatin calcium, ATOV:atovaquone, AZITH:azithromycin, 53 
CEL:celecoxib, DAN:danazol, FUR:furosemide, ITR:itraconazole, KET:ketoconazole, LAP:lapatinib, 54 
METF:metformin hydrochloride, METOP:metoprolol tartrate, NIF:nifedipine, PAR:paracetamol, 55 
PRAV:pravastatin sodium, PROP:propafenone hydrochloride 56 
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1. Introduction 58 
The presence of food in the gastric environment as a factor affecting drug dissolution 59 
and absorption has been extensively discussed in the literature over the last 30 years. Even 60 
though most drugs are mainly absorbed in the small intestinal environment, the role of the 61 
gastric environment is equally important; the stomach acts as a reservoir, with the presence of 62 
food having a significant influence on the absorption of drugs through various mechanisms 63 
such as delayed gastric emptying [1], increased gastric residence time [2] and interaction of 64 
drugs with meal components [3]. 65 
The FDA proposes the use of high fat standard meals for the determination of a drug’s 66 
food effect, as meals of high caloric and fat content can stimulate bigger changes in the 67 
gastrointestinal physiology and consequently have a more pronounced effect on drug 68 
bioavailability when this is affected by the presence/absence of food [4]. In theory, the optimal 69 
medium for the determination of food effect in vitro would be a homogenised standard meal, 70 
similar to the ones which have been successfully used for in vivo studies [5]. Due to difficulties 71 
in aspiration and handling of such a medium though [6], a range of biorelevant dissolution 72 
media has been developed in order to simulate the in vivo conditions of the fed state stomach. 73 
These media were developed with an aim of having the same physicochemical properties with 74 
the standard meal recommended by FDA for BA/BE studies [4]. 75 
Milk and milk-based media have been used as dissolution media for gastric fed state 76 
simulation for more than twenty years. Despite milk’s simplicity and convenience though, its 77 
energy content differs to that of a standard high-fat breakfast used in BA/BE studies [7] and 78 
does not accurately simulate the gastric fed state conditions, because of deviations in osmolality 79 
and buffer capacity compared to the FDA-proposed standard meal [5]. Moreover, its pH value 80 
is significantly higher (pH ≈ 6.5) than the gastric pH after a meal administration (5.8 ± 0.2 at 81 
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50% of the meal emptied by the gastric compartment, liquid meal administered) [8]. In order 82 
to improve the gastric environment simulation, a milk-based medium called Fed State 83 
Simulated Gastric Fluid (FeSSGF) was developed. This medium consists of 3.5% fat milk, 84 
diluted with acetate buffer at 1:1 ratio [6, 9]. Three FeSSGF versions with different pH values 85 
have been used so as to mimic the three phases of gastric digestion with the pH values being 86 
6.4, 5.0 and 3.0 for the early, middle and late phases respectively [10]. Despite its limited ability 87 
to simulate the gastric fed conditions at each point of ingestion, middle phase FeSSGF is used 88 
as a compromise for the reflection of the sum of gastric physiological events during ingestion 89 
[10]. Unlike aqueous media, laborious techniques are usually required for extraction of drug 90 
from these milk-based media. A study where the extraction process was avoided [11] used an 91 
ion selective electrode (ISE) sensor system with two electrodes constantly in the dissolution 92 
vessel offering the possibility of a continuous dissolution profile. The method though was 93 
limited to the analysis of ionised drugs, it required a complicated correction of the baseline and 94 
was unable to analyse compounds of extremely low aqueous solubility.  95 
Protein precipitation is the most frequently used sample clean-up technique, in which 96 
an organic reagent is added to the milk-based medium, followed by a centrifugation and a 97 
filtration step. Organic reagents like acetonitrile (added at 1:1 [12] and 1:2 [13, 14] 98 
medium:reagent ratios), isopropanol (1:1 ratio [15]) and ethyl acetate (1:4 ratio [16]) have been 99 
successfully used so far, but the rationale regarding the selection of the optimum reagent has 100 
not been yet clarified.  101 
Solid phase extraction (SPE) is another extraction technique widely used for the 102 
extraction of drugs from heterogeneous media and biological fluids such as whole blood [17], 103 
plasma [18], urine [19], and milk [20], often preceded by a protein precipitation step. SPE 104 
cartridges consist of a polypropylene tube with the sorbent placed between two porous frits. 105 
Most cartridges are either comprised of bonded silica phases, similar to the material of the 106 
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reversed phase HPLC columns but with bigger diameter particles (10-60 μm), or of polymeric 107 
resins (e.g. polystyrene-divinylbenzene) [21]. 108 
So far, there has been no specific guideline for the treatment of each compound 109 
according to its characteristics and every drug is examined separately as far as its effective 110 
extraction and quantification in fed gastric biorelevant media are concerned [22]. Due to the 111 
absence of a general in vitro predictive test, the aim of this study was the development of an 112 
optimised protocol for drug quantification in fed gastric biorelevant media, towards the build-113 
up of an in vitro predictive test of food effect observed in vivo. To achieve the above, an 114 
analytical protocol in milk-based fed gastric biorelevant media dictating the optimum sample 115 
treatment maximising the method sensitivity was developed, providing an analytical roadmap 116 
guide according to the drug’s physicochemical properties.  117 
For the current study, a series of compounds of a wide range of lipophilicity and 118 
ionisation were selected as model compounds for the development of the analytical protocol, 119 
assessing the efficiency of the two extraction techniques mentioned above; protein precipitation 120 
and solid phase extraction. An extension of the multiple linear regression model (MLR), partial 121 
least squares (PLS) regression was used to understand the impact of certain variables (drug 122 
lipophilicity, aqueous solubility, drug ionisation properties and protein binding) on the 123 
performance of two commonly used sample clean-up techniques for drugs dissolved in milk-124 
based fed state biorelevant media. Its main advantage compared to the latter is its ability to 125 
analyse data with collinear independent variables [23]. To our knowledge, this is the first time 126 
the creation of a general analytical guideline for a range of compounds in fed gastric media is 127 
being attempted. Moreover, an innovation of the study is the use of partial least squares 128 
regression in order to define the critical parameters which affect the efficacy of protein 129 
precipitation and solid phase extraction in fed gastric media, justifying their selection with 130 
statistical tools.  131 
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2. Materials and Methods 132 
2.1. Materials 133 
Furosemide (≥ 98% (HPLC), (±)-metoprolol (+)-tartrate salt (≥ 98% (titration)), 1,1-134 
dimethylbiguanide hydrochloride (metformin hydrochloride, 97%), danazol (≥ 98%), 135 
itraconazole (≥ 98% (TLC)), propafenone hydrochloride (≥ 98% (HPLC)), celecoxib (≥ 98% 136 
(HPLC)), azithromycin (≥ 95% (NT)) and atovaquone (≥ 98% (HPLC)) were all purchased 137 
from Sigma-Aldrich, UK. Nifedipine (98 to 102% (on dried substance)), paracetamol (97.5% 138 
min. (HPLC)), atorvastatin calcium (pharmaceutical secondary standard; traceable to USP, 139 
PhEur), atenolol (≥ 98% (TLC)) and ketoconazole (inclusive between 98%) were all purchased 140 
from Fisher Scientific, UK. Pravastatin sodium (≥ 98%) and lapatinib (≥ 99% (HPLC)) were 141 
purchased from Carbosynth, UK. MK-C1, MK-C2, MK-C3 and MK-C4 were provided by 142 
Merck & Co, INC, US. 143 
Sodium chloride, sodium hydroxide, sodium dodecyl sulphate, sodium acetate 144 
trihydrate, dipotassium hydrogen orthophosphate, potassium dihydrogen phosphate, 145 
ammonium acetate, hydrochloric acid 37% glacial acetic acid ≥ 99% and trichloroacetic acid 146 
10% w/v were all purchased from Fisher Scientific, UK. HPLC grade methanol, ethanol, 147 
acetonitrile, acetone, trifluoroacetic acid (≥ 99%) were all purchased from Sigma- Aldrich, UK.  148 
3.6% fat UHT milk was commercially purchased (Sainsbury’s, UK).  149 
Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 150 
LabHut Ltd, UK, Whatman 13 mm glass microfiber syringe filters 2.7 μm (GF/D) from Fisher 151 
Scientific, UK and SPE cartridges (Sep-Pak tC18 3 cc Vac Cartridge, 500 mg Sorbent per 152 
Cartridge, 37-55 µm Particle Size, Sep-Pak C8 3 cc Vac Cartridge, 500 mg Sorbent per 153 
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Cartridge, 37-55 µm Particle Size and Oasis HLB 1 cc Vac Cartridge, 30 mg Sorbent per 154 
Cartridge, 30 µm Particle Size) from Waters, UK.  155 
2.2. Instrumentation  156 
All samples were analysed in an HPLC system consisting of an Agilent 1200 series 157 
binary pump (G1312A), an Agilent 1200 series DAD detector (G1315D), an Agilent 1200 158 
series autosampler (G1329A), an Agilent 1200 series controller (G1316A) and a Chemstation 159 
software (Agilent Technologies, Santa Clara, United States).  160 
A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 161 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany), a 162 
vortex mixer Rotamixer (HTZ, Chesire, UK) and, a UV-Vis Thermo Spectronic Helios Gamma 163 
spectrophotometer (Thermo Scientic, UK) were used. 164 
2.3. Fed state medium selection 165 
Fed State Simulated Gastric fluid (FeSSGF) was selected as the working medium due 166 
to its simplicity in its preparation and stability for 72 h [10]. Its buffer capacity, osmolality and 167 
surface tension values are in total closer to the values measured in vivo after the administration 168 
of a standard meal than the equivalent properties of milk, which has been extensively used as 169 
a gastric fed state medium in dissolution studies [24]. Finally, as it is less viscous than milk, its 170 
handing and loading/elution from the SPE cartridges was feasible without back pressure.  171 
2.4. Medium preparation  172 
Fed State Simulated Gastric Fluid (FeSSGF) was prepared according to Jantratid et al. 173 
[10], by mixing 3.6% fat milk and acetate buffer pH = 5 (17.12 mM CH3COOH, 29.75 mM 174 
CH3COONa, 237.02 mM NaCl in the medium) at a 1:1 volume ratio. For the preparation of 1 175 
L of medium, 500 mL milk and 480 mL buffer were mixed under constant stirring using a 176 
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magnetic stirrer. pH was adjusted to 5 with 1 N HCl and the volume was adjusted to 1 L with 177 
the buffer.  178 
2.5. Pilot study and selection of optimum conditions 179 
20 drugs of a wide range of physicochemical properties (lipophilicity, ionisation, 180 
aqueous solubility and protein binding) were selected as model compounds (Table 1). 6 181 
compounds were selected for the pilot study in order to assess the optimum extraction 182 
techniques and protocols and determine the parameters affecting the extraction technique’s 183 
efficiency. The compounds selected for the pilot study were hydrophilic to extremely lipophilic 184 
(log P = -0.56–6.20) and included acids, bases and a neutral compound. Each compound’s % 185 
absolute recovery was expressed as described in the equation (Eq. 1) below, 186 
% absolute recovery=
Area of peak of filtered aliquot
Area of peak of standard solution of equivalent
 concentration in acetate buffer or MeOH: acetate buffer
                  (Eq. 1) 187 
where filtered aliquot denotes the filtered drug solutions after protein precipitation or elution 188 
from the SPE cartridge. 189 
In protein precipitation, four organic and three aqueous reagents were tested to determine 190 
the highest % absolute recovery values: methanol (MeOH), ethanol (EtOH), acetonitrile (ΑCN) 191 
and acetone [organic reagents] and 2M HCl, 10% w/v trichloroacetic acid (TCA) and 10% w/v 192 
trifluoroacetic acid (TFA) [aqueous reagents]. Four different FeSSGF:precipitation reagent 193 
ratios (1:1, 1:2, 1:3 and 1:5) were tested to determine possible differences in % absolute 194 
recovery and two different concentrations (a “high and a “low”, defined below Table 1) in order 195 
to assess the method efficiency at a range of drug concentrations. The parameter assessed in 196 
SPE was elution volume, using tC18 cartridge (2 mL and 5 mL). 197 
The efficiency of two extraction techniques [protein precipitation (PP) and solid phase 198 
extraction (SPE)] was investigated in the pilot study with the optimised protocol being applied 199 
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to all compounds in Table 1. The optimum conditions (drug concentration, reagent and ratio) 200 
were selected and applied to all model compounds. The minimum efficiency limit for the pilot 201 
study was arbitrarily set to 50% (absolute recovery > 50%) [the 50% threshold was selected in 202 
order to obtain a final drug concentration in the extracted medium of not more than ~10 times 203 
lower than the initial drug concentration in the FeSSGF, and keep method sensitivity as high 204 
as possible]. Higher ratios (1:1, 1:2 were generally preferred due to higher method sensitivity 205 
(no need for dilution to overcome peak fronting). Similarly, for SPE, lower elution volume was 206 
preferred in case of similar recovery values. A 15% limit was set as the acceptable threshold 207 
for % CV in the final study with all the compounds tested under the optimum extraction 208 
conditions. The limit was selected in line with the regulatory requirements for acceptable 209 
variability in recovered samples as proposed by the EMA [51] and FDA [52] in the guidelines 210 
for bioanalytical method validation. 211 
2.6. HPLC analysis 212 
Stock solutions of the drugs were prepared in MeOH, EtOH, ΑCN or H2O, based on 213 
the drug solubility in the above solvents. Calibration standards were prepared in organic 214 
solvent:“blank” acetate buffer 1:1 (pH adjusted to 5) mixture or acetate buffer pH 5, (where 215 
organic solvent is MeOH, EtOH or ΑCN, according to drug solubility in organic solvents). The 216 
drugs were analysed in HPLC with published HPLC methods (or modifications of published 217 
methods) which are stated in Table 2. 218 
Adsorption studies were performed in triplicate for each model drug for all types of 219 
filters used. No adsorption issues were observed for the drugs studied. 220 
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2.7. FeSSGF solubility studies 221 
Where FeSSGF or milk solubility data was not available in the literature, drug 24 h- 222 
solubility values in FeSSGF were determined by using a modification of a protocol using the 223 
shake-flask method [15]. The solubility of the model compounds was determined by weighing 224 
excess amounts of the drug into 5 mL Eppendorf tubes, followed by the addition of 5 mL of 225 
FeSSGF. The samples were left to equilibrate in a shaking water bath at 37 °C for 24 hours, 226 
and then filtered through a GF/D filter of 2.7 µm pore size. 1 mL of ΑCN was added to 0.5 mL 227 
of the filtered sample, vortexed for 30 sec and centrifuged (15 min, 8000 rpm, 4 °C). The 228 
supernatant, was filtered through a 0.45 μm RC filter, diluted and analysed using HPLC. Drug 229 
was quantified against calibration standards in FeSSGF which had undergone the same 230 
treatment as the sample. Each measurement was performed in triplicate. 231 
2.8. Protein precipitation (PP) 232 
2.8.1. Protein precipitation methodology  233 
1 mL of working solution of each drug in FeSSGF was placed in a plastic centrifuge 234 
tube. A volume of the protein precipitation reagent according to the FeSSGF:protein 235 
precipitation reagent ratios as defined below (1, 2, 3, 5 mL) was added. The mixture was 236 
vortexed at full speed for 30 sec and centrifuged at 8000 rpm (9800 × g) for 15 minutes (4 °C). 237 
The supernatant was filtered through a 0.45 mm RC filter and assayed. The sample was diluted 238 
with acetate buffer or MeOH:acetate buffer 1:1 when diluent was more highly eluting than the 239 
mobile phase and peak shape needed to be improved.  240 
 241 
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2.8.2. Matrix interference 242 
Full scans of the supernatants of the six drugs used in the pilot study plus atovaquone 243 
(a compound which demonstrated big differences in recovery between the three optimum 244 
reagents used.), with MeOH, acetonitrile and 10% w/v TCA used as protein precipitation 245 
reagents, were performed using the diode array detector of the HPLC instrument, to determine 246 
possible interferences from the medium and precipitation reagents in drug analysis. Scans were 247 
performed over a range from 190 to 400 nm. Standards were prepared in a mixture comprising 248 
one part of buffer and two parts of PP reagent so as to maintain the same amount of precipitation 249 
reagent as the extracted FeSSGF samples with the selected reagents. Spectra of a supernatant 250 
after proteins were precipitated with a specific reagent and spectra of the same drug, dissolved 251 
in 1 part of acetate buffer pH = 5 and 2 parts of the selected protein precipitation reagent were 252 
normalised to peak intensity and superimposed using the “best possible match of the entire 253 
spectrum” mode in Chemstation software. Chromatograms of drug samples were compared 254 
against “blank” samples (one part of FeSSGF + two parts of protein precipitation reagent) to 255 
determine possible interferences for the medium. 256 
2.9. Solid phase extraction (SPE)  257 
Three different types of cartridges were used: tC18 (500 mg bed weight), HLB (30 mg 258 
bed weight), C8 [(500 mg bed weight)-used for the extraction of metformin hydrochloride 259 
only]. The extraction cartridges were conditioned by washing with 5 mL [tC18 (trifunctional 260 
octadecyl silica), C8] or 1 mL MeOH (HLB), followed by 5 mL and 1 mL of H2O respectively. 261 
1 mL of FeSSGF was loaded and the columns were 5 washed with 5 mL and 1 mL of H2O 262 
respectively. The drugs were eluted with 5 or 2 mL MeOH:H2O 70:30 (tC18 and C8 cartridges) 263 
or 1 mL MeOH (HLB cartridges).  264 
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As in the case of protein precipitation, a pilot study with the initial six compounds was 265 
performed and the optimal conditions of the parameters examined were applied for the rest of 266 
the model compounds. Modifications of the above protocols were performed in cases of % 267 
absolute recovery values < 50%, with different approaches according to each drug’s 268 
physicochemical properties and are described in detail in SPE protocol optimisation part of 269 
Results and Discussion section. Protocols were optimised by: modifications in cartridge 270 
conditioning (a. use of an ion-pair reagent, b. conditioning of the cartridge with an acid or a 271 
base so as to improve its retention characteristics) or modifications in elution (a. use of 272 
different elution solvents, b. addition of acid or base in elution solvent so as to increase its 273 
elution strength). Specifically: 274 
Metformin: A C8 cartridge which retains hydrophilic compounds better was used and 275 
either the washing step was omitted or the HLB cartridge was pre-treated with 2 mM Sodium 276 
dodecyl sulphate (SDS) solution before the loading step. SDS was selected based on the 277 
hypothesis that due to the stationary phase’s chemistry, the equilibration of the HLB cartridges 278 
with an ion pair reagent would lead to the retention of the drug to the cartridge through 279 
development of hydrophobic interactions between drug and cartridge with the complex easily 280 
be broken during the elution of the drug with an organic elution solvent [69]. Atovaquone, 281 
Lapatinib, MK-C1, MK-C2, MK-C3, MK-C4: Elution with MeOH for the more effective 282 
disruption lipophilic interactions between the drug and the lipophilic chains of the tC18 283 
cartridge. Itraconazole: Pre- treatment of the cartridge (HLB) with 0.01 M NaOH (to retain the 284 
drug (weak base) on the cartridge and elution with 0.25 M formic acid in MeOH for a more 285 
efficient elution in its ionised form. 286 
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2.10. Statistical Analysis 287 
Comparisons were performed in order to assess significant changes in drug recovery 288 
using different precipitation reagents, medium:reagent ratios, drug concentration, different SPE 289 
cartridges and elution volumes. For protein precipitation, % absolute recovery and correlation 290 
with added protein precipitation reagent, (FeSSGF:reagent ratio) and drug concentration were 291 
evaluated in the context of a multiple way Analysis of Variance (ANOVA) (Statgraphics v. 292 
XVI, StatPoint Technologies Inc, US) with a post-hoc Bonferroni test. In solid phase 293 
extraction, effect of different elution volumes and cartridges on drug % absolute recovery were 294 
compared using a two-tailed t-test. (Statgraphics v. XVI). Comparisons where p < 0.05 295 
suggested a statistically significant difference.  296 
The absolute % drug recovery using different protein precipitation or SPE protocols 297 
was correlated to drug physicochemical properties by partial least squares (PLS) regression 298 
using the XLSTAT software (Microsoft, US). The parameters evaluated were: lipophilicity 299 
(log P), log aqueous solubility in mg/mL, drug unionised fraction at pH = 5, acid/base 300 
properties and drug protein bound fraction in plasma proteins (drug bound fraction to plasma 301 
proteins was used as an indicator of protein affinity due to the lack of available data in milk 302 
proteins in the literature). The physicochemical properties selected as independent variables 303 
were decided on the basis of their potential effect on drug distribution in the aqueous and lipid 304 
phases of the medium and its interaction with milk proteins. PLS regression analysis was 305 
performed with % recovery of the three reagents used for the extraction of the 20 model 306 
compounds being the dependent variable. Selected interactions were also included in the model 307 
(log P*log aqueous solubility, log P*acid/base properties, aqueous solubility*drug unionised 308 
fraction, aqueous solubility*acid/base properties, unionised fraction*acid/base properties). The 309 
model quality was evaluated on the square of the coefficient of determination (R2) and 310 
goodness of prediction (Q2). R2 and Q2 values close to 1 refer to a model of good fit and 311 
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prediction power respectively while a difference lower than 0.2-0.3 between them is indicative 312 
of a successful model [70]. Full cross-validation (leave-one-out procedure) was used to develop 313 
and evaluate the regression model. The optimum number of calibration factors for each model 314 
was selected based on the model’s optimum predictability (Q2) and predicted residual error 315 
sum of squares (PRESS). A Q2 value > 0.5 is generally considered acceptable for good model 316 
predictability [71]. Lower PRESS values indicate better prediction [72] with the number of 317 
latent variables where PRESS starts increasing indicating the number of variables which to be 318 
retained in the model [73]. The standardised coefficients of the factors plotted indicate the 319 
relative positive/negative effect of their corresponding variables on the % drug recovery 320 
(response value). High standardised coefficients for variance X have a big positive or negative 321 
effect on response Y. The importance of each parameter was evaluated by its variable 322 
importance in projection (VIP) value. Values above 1.0 are considered to have a significant 323 
effect on the dependent variable, whereas values < 0.7-0.8 are not of significance for the 324 
prediction of the dependent variable [70].  325 
2.11. Roadmap design 326 
The roadmaps leading to selection of optimal protein PP and SPE protocols for drug analysis 327 
were constructed combining the results from the complete study for the 20 model drugs (and 328 
selected PP and SPE conditions) and the variables affecting the drug percentage recovered, as 329 
demonstrated by the PLS regression analysis. Only models with Q2 values > 0.5 were 330 
considered for the roadmap design. For protein precipitation, optimum conditions were selected 331 
on the basis of absolute % recovery. If absolute % recovery was > 85% for more than one 332 
reagent, MeOH or 10% w/v TCA were preferred over ΑCN, as they give peaks of better shape 333 
without the need of dilution. The 85% threshold was only used as a selection criterion, between 334 
protein precipitation obtained with acetonitrile or methanol. The limit was based on the method 335 
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capability as both methods gave recoveries consistently close to 100% for most drugs. 336 
Therefore, the 85% (100% - acceptable 15% CV, in line with the regulatory guidelines) [51, 337 
52] was set in order to select the optimum protocol according to its maximum potential. 338 
 339 
3. Results and Discussion 340 
3.1. Drug analysis: Optimisation of protein precipitation conditions 341 
3.1.1. Pilot study and selection of optimum extraction conditions  342 
When added to media containing proteins, organic reagents act by decreasing the 343 
dielectric constant of the proteins of the medium, a. increasing electrostatic interactions 344 
between them and b. displacing water molecules around their hydrophobic areas. Thus, their 345 
solubility in the medium decreases, leading to aggregation and protein precipitation [21]. 346 
All four organic reagents used (MeOH, EtOH, ΑCN, acetone) gave acceptable recovery 347 
values (> 69.5%) for the six model compounds in the pilot study with clear supernatants for 348 
drugs’ analysis in the HPLC after filtration (Figure 1). The only exception was EtOH when 349 
used as a precipitation reagent for danazol (Figure 1), which resulted in poor peak shape in 350 
HPLC despite the dilutions made. 351 
Acidic reagents act by forming insoluble salts with the positively charged amino acids 352 
of a milk-based medium at pH below their isoelectric point [21]. The use of weak acids as 353 
protein precipitation reagents may be challenging for drugs demonstrating instability in acidic 354 
conditions. Hydrochloric acid, trichloroacetic acid and trifluoroacetic acid were particularly 355 
effective as precipitation reagents giving high recovery values (92.4–106.7%) for all ratios of 356 
the hydrophilic (metformin, metoprolol) drugs (Figure 1). They were not able to recover high 357 
amounts of the two most lipophilic drugs (danazol, itraconazole) from the medium though, 358 
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with 2.4 ± 0.1% maximum recovery at a 1:5 ratio for danazol and 0% recovery for all ratios for 359 
itraconazole achieved. As expected, a reason for the poor recoveries of lipophilic compounds 360 
in acidic reagents is their lower aqueous solubility, which is a barrier for the extraction potential 361 
of compounds of similar lipophilicity. The two weak acids (nifedipine, furosemide) were 362 
partially recovered using acidic reagents with the recovery percentage ameliorating by 363 
decreasing the FeSSGF:reagent ratio. The two weak bases (metformin, metoprolol tartrate) 364 
were almost 100% recovered at all ratios (Figure 1).  365 
A three-way analysis of variance showed that the selection of protein precipitation 366 
reagent affected the % recovery values for all six drugs of the pilot study (p < 0.05) (Figure 2). 367 
Acetonitrile was proven the most effective (higher mean absolute recovery) for three out of six 368 
drugs, acetone for two and ethanol for one compound respectively in terms of mean absolute 369 
recovery. The presence of NaCl in the medium can increase drug recovery when acetone is 370 
used as a protein precipitation reagent. Crowell et al. [74] demonstrated that in acetone 371 
concentrations between 50 and 80% of the total mixture, NaCl concentrations > 10 mM in the 372 
medium led to protein % recovery values close to 100% for a number of proteins, such as α-373 
casein, β-lactoglubulin and bovine serum albumin which are present in milk [75]. The effective 374 
entrapment of proteins in the precipitate possibly led to an increased amount of free drug 375 
available in the supernatant, resulting in higher recovery. Differences in efficiency among 376 
precipitation reagents can be attributed to the remaining proteins in the supernatant; since 377 
protein precipitation can only remove the larger proteins, leaving small proteins and peptides 378 
behind. These may interfere with the compounds of interest and have unpredictable effects 379 
(such as unexpectedly low drug recoveries) on drug quantification [21]. 380 
The effect of the FeSSGF:precipitation reagent ratio was evaluated in the pilot study 381 
for achieving maximum absolute drug recovery and adequate method sensitivity. Decreasing 382 
the medium:precipitation reagent ratio (from 1:1 to 1:5) did not show profound differences in 383 
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drug absolute recovery as far as organic reagents were concerned. With the exception of 384 
itraconazole, for which the % absolute recovery increased from approximately 78% to 99.9-385 
106.6% when decreasing the FeSSGF:organic reagent ratio from 1:1 to 1:2, 1:3 and 1:5, all 386 
organic reagents resulted in % absolute recovery > 80% at all ratios used (Figure 2). A higher 387 
amount of organic solvent may increase the percentage of drug recovered by reducing solvation 388 
of the proteins in the aqueous medium, causing their precipitation. The statistical analysis 389 
showed that the ratio in which the precipitation reagent was added was statistically important. 390 
Reported p values for 4/6 drugs used in the pilot study were < 0.05 with the recoveries of 391 
metoprolol tartrate and danazol not being affected (p = 0.86 and 0.66 respectively) by the 392 
amount of precipitation reagent added (Figure 2). For the other drugs, 3 or 5 parts of protein 393 
precipitation reagent added in 1 part of FeSSGF resulted in higher % drug recovery than 1 part 394 
of reagent added to 1 part of FeSSGF prior to vortexing and centrifugation (Figure 1; red parts 395 
of the contour plot). Even though the differences among the protocols with different ratios were 396 
statistically significant, the difference may not always be practically important, as in most cases 397 
the method efficiency threshold set for the study (50 % absolute recovery) was met. Nifedipine 398 
is given as an example; the addition of 1 part of methanol in 1 part of FeSSGF, recovered 399 
approximately 101% of the drug, while addition of 5 parts recovered approximately 107% 400 
(Figures 1, 2). The same protocol by using 10% w/v TFA resulted in 26% and 72% values 401 
respectively. It is obvious that in the first case selection of a 1:5 ratio would not improve the 402 
extraction method but it would result in a loss of sensitivity, due to a bigger dilution of the 403 
medium with methanol. In the second case though, the difference is notably important and 404 
therefore for a compromise, % recovery, desired method sensitivity and HPLC method 405 
compatibility with the medium have to be considered. 406 
Drug concentration had an effect on the percentage recovered using organic or aqueous 407 
solvents for protein precipitation. For the hydrophilic base (metformin), the % recovery values 408 
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were not affected by the drug concentration (p > 0.05) (Figure 2). In all other drugs of the pilot 409 
study, drug at high concentration was more effectively recovered (p < 0.05). Similarly to the 410 
example given above for the effect of protein precipitation ratio, the average difference 411 
between recoveries of “high” and “low” concentrations as given by the post-hoc Bonferroni 412 
test lied within a range between 0.5 and 12.3% in the range of drugs studied, with the highest 413 
recovery observed for “high” concentrations. Despite the slight differences in absolute 414 
recovery between concentrations, the method can still be used for drug analysis if the 50% 415 
absolute recovery limit is met and linearity is proven in the working concentration range. 416 
Reagents added at a 1:3 or 1:5 ratio to FeSSGF often dilute the sample significantly, driving 417 
its recovery below the LOQ of the method for the “low” concentration (Figure 2).  418 
The reagents (two organic and one aqueous) selected were methanol, acetonitrile and 419 
10% w/v trichloroacetic acid at a 1:2 FeSSGF: reagent ratio with the rationale of selection 420 
explained in the Methods part. Since the pilot study proved that the volume of reagent added 421 
for protein precipitation was statistically important, a relatively high reagent: FeSSGF ratio 422 
was selected (1:2), so that high % recovery and adequate method sensitivity could be 423 
maintained. For the final study and assessment for the rest of the model compounds, the highest 424 
of the two concentrations, which gave higher % recovery values in the pilot study was chosen.425 
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3.1.2. Main study and selected protocol application 426 
The two organic reagents used, methanol and acetonitrile, added at a 1:2 427 
FeSSGF:reagent ratio, gave high recovery values for all the compounds over a wide range of 428 
lipophilicity (log P = -0.56-8.81) and ionisation with the exceptions of atovaquone and MK-429 
C4. Atovaquone (log P = 5.07) was only recovered by 33.4% at 25 μg/mL in FeSSGF when 430 
methanol was used, while acetonitrile recovered 82.2% of the same drug concentration (Figure 431 
3). For drug extraction using acetonitrile, atovaquone studies in plasma [76] and whole blood 432 
[77] gave similar results to our study. For methanol, since atovaquone’s solubility in it is much 433 
higher than the concentration used, a possible reason of the significantly low recovery values 434 
could be the loss of analyte due to its occlusion in the precipitate [78]. The drug’s extremely 435 
high affinity for plasma proteins (> 99.5% bound) [79] and its high affinity to fat, as described 436 
in in vivo studies which showed increased drug bioavailability after co-administration with a 437 
high fat meal [80], could indicate a strong interaction with fat or proteins of the fed state 438 
medium. This interaction may have not been disrupted by the application of methanol, with the 439 
drug being entrapped in the precipitate.  440 
The aqueous reagent (10% w/v TCA) added at the ratio mentioned (1:2) was proven 441 
effective only for highly soluble (aqueous solubility > 100 μg/mL) APIs with log P values < 2 442 
with the % recovery of weak bases (metformin hydrochloride, metoprolol tartrate, atenolol, 443 
paracetamol), approaching 100% (Figure 3). The above compounds were mostly unionised at 444 
pH 5, but were likely negatively ionised at the low pH of the acidic supernatant. Precipitation 445 
with trichloroacetic acid gave poor recovery values (0%) for atovaquone, because the drug as 446 
a lipophilic weak acid co- precipitated with the proteins [81]. The same applied for MK-C4 447 
(log P = 8.81), which is an extremely lipophilic drug with high affinity for adipose tissue [82].  448 
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% recovery values lower than 100% when organic reagents were used for protein 449 
precipitation were probably not attributable to the interaction of the drug with protein 450 
molecules of the supernatant, but due to its entrapment in the precipitate. This hypothesis was 451 
confirmed by superimposing the spectra of the supernatant and drug standards in an acetate 452 
buffer:precipitation reagent mixture. The drugs selected demonstrated variable % recovery 453 
values in the three reagents selected (methanol, acetonitrile, 10% w/v TCA). Nevertheless, the 454 
spectra were identical in all cases despite high or low % drug recovery values and no other 455 
interference was observed in the peak of the drug. Moreover, the retention time of all drugs in 456 
the chromatogram remained constant, which implied that there was no change in the structure 457 
of the drug molecule (data not shown). Therefore, the results indicated that the drug quantified 458 
was the free drug in solution without any interference from the biological matrix.  459 
The % recovery obtained for all drugs was below the 15% threshold set for the 460 
coefficient of variation (Figure 4), with samples extracted using TCA demonstrating the highest 461 
variability, but still within the proposed limits. 462 
3.1.3. Prediction of the effect of physicochemical properties on extraction protocol (PP) 463 
selection 464 
The variables and their interactions of the PLS models examined are summarized in 465 
Figure 5. The PLS models constructed for % recovery values when MeOH, ΑCN and 10% w/v 466 
TCA were used as protein precipitation reagents were defined by 1, 1 and 2 Principal 467 
Components respectively. The PLS model developed for 10% w/v TCA was a good fit to the 468 
experimental values (R2 = 0.87) and showed good predictive power (Q2 = 0.83). The models 469 
developed for MeOH and ΑCN can only account for a very low percent of Y variability (R2 = 470 
0.34 and 0.23 respectively), and have limited predictive power (Q2 = 0.24 and 0.05 471 
respectively), according to the threshold (Q2 = 0.5) set for the study.  472 
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The model demonstrated that lipophilicity (log P) is defined as negative predictor for 473 
% drug recovery in all three cases when MeOH, ΑCN and 10% w/v TCA were used as protein 474 
precipitation reagents in FeSSGF treatment with its effect in the cases of MeOH and TCA 10% 475 
w/v being statistically significant, as indicated by the high VIP factor (Figure 5). A higher 476 
partition coefficient indicates higher tendency of the solutes distribution to the lipid phase of 477 
the medium [83], which could be limiting the extraction potential of the reagent.  478 
In cases where methanol was selected as protein precipitation solvent, drug lipophilicity 479 
affected the extraction of compounds regardless of their ionisation state, with a bigger effect 480 
on neutral and acidic compounds (VIP > 1), and compounds being in the unionised state in the 481 
working pH, as indicated by the negative standardised coefficients of log P interactions with 482 
the properties mentioned. Drug distribution in the lipid medium fraction is facilitated for 483 
unionised drugs, as ionised molecules have to dispose a part of their hydration water in order 484 
to permeate the lipid bilayer, a process energetically unfavourable [84]. The above observations 485 
of the drug physicochemical properties which affect extraction from FeSSGF using methanol, 486 
denote that even though the effect of ionisation percentage does not have a significant impact 487 
by itself, it can have a negative effect on the amount recovered in lipophilic drugs.  488 
For the use of 10% w/v TCA in protein precipitation, the main factors governing the % 489 
recovery are the drug’s log P, drug bound protein fraction (negative effect) and its aqueous 490 
solubility (positive effect). Even though the exact mechanism of protein precipitation is not 491 
fully understood, a proposed mechanism of action suggests the segregation of the protein bound 492 
water, with the type of the proteins not affecting the method efficiency, which is also acid-493 
concentration dependent [85]. The concentration of TCA used in the current study may only 494 
be adequate to precipitate a portion of proteins, with the drugs highly bound to proteins being 495 
trapped in the precipitate. High lipophilicity and high aqueous solubility as negative and 496 
positive predictors respectively may be explained by the aqueous nature of the precipitation 497 
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reagent. Moreover, the fact that the interactions of drug protein bound fraction with log P and 498 
aqueous solubility have a negative effect on drug recovery, strengthens our hypothesis that the 499 
inability of the TCA to break the drug-protein interactions under the stated experimental 500 
conditions is an unfavourable factor, even for the extraction of water soluble drugs. Similarly 501 
to what was observed in the pilot study, PLS regression showed that TCA is a suitable reagent 502 
for highly soluble weak bases (positive log aq sol*base interaction, Figure 5), while it affects 503 
the extraction of lipophilic bases or bases which are unionised in the medium’s pH in a negative 504 
manner, which was demonstrated by the negative log P*base and union fr*base negative 505 
standardized coefficients (Figure 5).  506 
The lack of the model’s predictive ability when ΑCN was used as a PP reagent can be 507 
explained by the reagent’s extremely high extraction ability in the whole range of drugs (> 90% 508 
recovery for 17/20 drugs studied) and low variance, with most values falling close to 100%.  509 
3.1.4. Designing a roadmap for effective sample treatment using protein precipitation 510 
In summary, MeOH and ΑCN can be effective for drugs exhibiting a wide range of 511 
lipophilicity and the use of one of the other is usually effective for drugs of log P values of -512 
0.5 to 5 (Figure 6). For hydrophilic to moderately lipophilic bases (metformin, metroprolol 513 
tartrate, log P < 2), the use of 10% w/v TCA was preferred over the two organic solvents, due 514 
to a better peak shape in the HPLC analysis. According to the findings of the PLS regression 515 
analysis, TCA is the most efficient reagent (higher absolute % recovery) for highly soluble 516 
drugs and drugs which exhibit a low affinity for proteins. Drugs of moderate lipophilicity were 517 
equally well recovered using either MeOH or ΑCN, therefore, both reagents could be used for 518 
the extraction of drugs of log P between 2 and 5. Issues with low % recovery with the use of 519 
MeOH were only encountered with some drugs of extreme lipophilicity (log P > 5), for which 520 
ΑCN was the most effective option (atovaquone, MK-C4). Consequently, ΑCN would be the 521 
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best choice of the three reagents (Figure 6), as drugs at this log P range were in all cases at 522 
more than 80%, while the use of MeOH and 10% w/v TCA could give absolute recoveries as 523 
low as 24 and 0% respectively. Therefore, taking the method’s high recovery and low 524 
variability obtained into consideration, we suggest that protein precipitation may be used in 525 
biorelevant dissolution and solubility studies with the use of a single correction factor based 526 
on the drug % recovery obtained, when a single calibration standard in FeSSGF is used. For 527 
the accurate determination of a dissolution profile the analyst should consider using at least 528 
one second calibration point for the quantification of drug released in the initial time points. 529 
As demonstrated in the pilot study, drug recovery is concentration dependent. Calibration 530 
standards prepared in triplicate would be required for the low concentration, in order to 531 
compensate for the higher variability of the method. 532 
3.2. Drug analysis: Optimisation of solid phase extraction conditions 533 
3.2.1. Pilot study and effect of elution volume 534 
The results of the pilot study, where tC18 cartridge was selected as a starting point are 535 
presented in Figure 7b. It can be seen that the specific cartridge can be effectively used for a 536 
range of compounds from moderately polar to non-polar. Drugs of log P between 0.74 and 4.2 537 
were recovered at a percentage higher than 60% (Figure 7b). Even though the minimum elution 538 
solvent (2 mL) is higher than two bed volumes (500 mg sorbent = 600 μL bed volume) which 539 
is required for effective extraction [21], it was shown that elution with 5 mL increased the % 540 
recovery values by a significant amount (p < 0.05) compared to 2 mL for all compounds of the 541 
pilot study (from 6.5% increase for nifedipine to 1700 % increase for danazol) (Figure 7b). 542 
Therefore, 5 mL was selected as the elution volume to proceed with the rest of the model 543 
compounds.  544 
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3.2.2. Effect of cartridge 545 
The results of the complete study where the cartridges and elution conditions selected 546 
were applied for all of the model compounds are presented in Figure 7a. tC18 cartridges can 547 
generally be used for a range of compounds from moderately polar to non-polar. Non-polar 548 
parts of the analyte develop Van der Waals interactions with the C18 non-polar groups of the 549 
sorbent, leading to selective retention of the analyte of interest, before its elution with an 550 
appropriate elution solvent. HLB was another type of sorbent used in this study and is a co-551 
polymer comprised of two different monomers; one hydrophilic (N-vinylpyrrolidone) and one 552 
hydrophobic (divinylbenzene). The use of HLB cartridges has also been found to be effective 553 
for both polar and non-polar compounds [86]. 554 
For compounds of log P values between 1.95 and 4, there was no clear pattern as to 555 
which should be selected in favour of the other for optimum % recovery values using log P as 556 
a selection criterion. Nevertheless, the use of one or the other cartridge (tC18 or HLB) in 557 
compounds of moderate lipophilicity (log P 2-4) recovered a minimum value of 69.5% of the 558 
initial compounds in FeSSGF for the optimum protocol at each case (Figure 7a). MK-C1, a 559 
compound on the verge of the threshold set for moderate lipophilicity (log P = 4) was poorly 560 
recovered in all cases 1.76 ± 0.33% and 0.15 ± 0.0 %for tC18 and HLB cartridges respectively. 561 
Its recovery was not improved despite protocol modification (tC18 and elution with MeOH, 562 
recovery = 8.80 ± 0.61). 563 
For most hydrophilic and lipophilic compounds, HLB was proven more effective, as it 564 
increased the % recovery values of the compounds which could not be effectively extracted (< 565 
15% absolute recovery) using tC18 cartridges (metformin hydrochloride, paracetamol, 566 
atovaquone, itraconazole, MK-C1, MK-C2, MK-C4), but not always to a great extent. For the 567 
drugs which could not be effectively extracted with the protocol used with tC18 cartridges, a 568 
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switch to HLB achieved a meaningful improvement in extraction performance only for 569 
paracetamol and MK-C2 (Figure 7a).  570 
SPE was incompatible with the extremely lipophilic model drugs studied. Using the 571 
current protocols, the recoveries of drugs of extreme lipophilicity (log P > 5) were higher with 572 
the use of HLB cartridges but still relatively low (5.7 ± 0.2%, 27.9 ± 0.7%, 22.1 ± 3.5% and 573 
0% against 1.9 ± 0.1%, 0 %, 15.3 ± 0.2% and 0% for tC18, for atovaquone, itraconazole, 574 
lapatinib, and MK-C4 respectively (Figure 7a). Previous studies with extraction of itraconazole 575 
with HLB cartridges from biological matrices demonstrated higher recovery values than the 576 
ones presented in this study. Although HLB cartridges have been more successfully used for 577 
extraction of itraconazole, these studies were in blood, [87] plasma [88] and surface waters 578 
[89] and the cartridges could be incompatible with the fed state medium used. The modification 579 
proposed in the methodology did not improve the recovery of the drug.The low recoveries of 580 
the extremely lipophilic compounds and the lack of pattern in terms of cartridge selection for 581 
the extraction of the moderately lipophilic compounds could indicate that the critical parameter 582 
for SPE optimisation is not the log P value of an API, but the type of interactions it develops 583 
with components (lipids, proteins) of the milk-based matrix. For atovaquone, 5 mL MeOH 584 
were also tested with tC18 cartridge giving somewhat better results but still low recovery values 585 
(17.5 ± 0.6 %) (Figure 8). The poor SPE recovery values for the specific drug, along with the 586 
low % recovery when MeOH was used in protein precipitation, supports the initial hypothesis 587 
that strong interaction with components of the fed state medium could be the main obstacle 588 
which has to be surpassed for effective extraction. In the cases of lapatinib, MK-C1, MK-C2, 589 
MK-C3 and MK-C4, 100% methanol was used as elution solvent in order to increase the 590 
protocol efficiency with tC18 cartridges with the stronger elution volume improving the 591 
percentage of drug eluted significantly in all drugs apart from MK-C3. Drug analysis results 592 
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for which modification of the SPE protocol led to an increase in % recovery are presented in 593 
Figure 8.  594 
For hydrophilic drugs (log P < 2), significant difficulties in effective drug recovery 595 
were encountered only in the case of metformin. Metformin is an extremely polar molecule 596 
which lacks hydrophobic functional groups. It was suggested that, due to the molecule’s 597 
polarity, retention on the cartridge’s hydrophobic functional groups was poor. While SDS 598 
conditioning did improve the recovery of metformin, the amount of drug recovered was still 599 
low (< 10%, data not shown). The most effective strategy in the case of metformin was the 600 
omission of the washing step. The omission of the washing step (tC18 and HLB cartridges), 601 
which improved the % recovery significantly (≈ 34% and 20% respectively-data not shown), 602 
was a far more effective strategy. Its combination with a change to a more hydrophilic cartridge 603 
like C8, a recovery value of 49.6 ± 1.9%, just below the acceptable recovery limit, was achieved 604 
(Figure 8). The functionalization of its silanol groups comprises of chains of eight carbon 605 
molecules instead of the eighteen like in tC18, therefore it is suggested that the drug is retained 606 
to the column via weaker hydrophobic interactions with the stationary phase’s silanol groups 607 
which are easier to break.  608 
Our observations for metformin and itraconazole (extremely hydrophilic and extremely 609 
lipophilic compounds respectively) (Figures 7a,b) were in agreement with previous studies 610 
which suggested that C18 cartridges are often a poor choice for drugs of extreme or poor 611 
hydrophilicity. Metformin [90] and itraconazole [91] were recovered by < 20% and < 40% 612 
respectively when eluted from C18 cartridges using methanolic solutions (studies in aqueous 613 
solutions and human liver microsomal’ fraction respectively). Recoveries using the two 614 
different cartridges were significantly different in the majority of cases, (p < 0.05, 16/20 drugs), 615 
in the range of model compounds studied (Figure 7a), meaning that selecting one over the other 616 
can have a significant impact on the amount of drug to be recovered using a specific protocol 617 
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in a study. Sample variability obtained with solid phase extraction was significantly higher than 618 
the variability observed using the protein precipitation protocols developed. For five of the 619 
drugs tested (metoprolol tartrate, pravastatin sodium, celecoxib, MK-C1 and lapatinib) the % 620 
CV obtained was above the variability threshold set for the study (Figure 4). No apparent 621 
differences were observed between the different cartridges or trends related with drug 622 
lipophilicity.  623 
3.2.3. Prediction of the effect of physicochemical properties on extraction protocol (SPE) 624 
selection 625 
 The variables and their interactions of the PLS models examined are summarized in 626 
Figure 9. The PLS models constructed for % recovery values when tC18 and HLB cartridges 627 
were used (standard protocol) were defined by 1 and 3 Principal Components respectively. The 628 
PLS model developed for HLB was a good fit to the experimental values (R2 = 0.87) and 629 
showed good predictive power (Q2 = 0.83), while the model developed for the SPE extraction 630 
using a tC18 cartridge can only account for a low percent of Y variability (R
2 = 0.34), and has 631 
poor predictive power (Q2 = 0.24). In both cases, the parameter having the most prominent 632 
positive effect was the log P*log aqueous solubility interaction (Figure 9), which is attributed 633 
to retention of a higher amount of drug in the SPE cartridge during the initial loading step, and 634 
also a more effective elution using a polar MeOH or MeOH/H2O solvent in the elution step. In 635 
tC18, drug lipophilicity alone, but also its interactions with basic and neutral compounds, 636 
affected drug extraction negatively. The same applied for compounds which act as ampholytes 637 
in an aqueous environment while acidic compounds were easier to extract (positive 638 
standardised coefficient for weakly acidic compounds, VIP > 1). The recovery dependence of 639 
the compounds’ ionisation state can be attributed to the presence of ionic interactions between 640 
charged drugs with the residual silanol groups of the cartridge which are unable to break with 641 
unbuffered MeOH:H2O elution solvents [92]. Similar conclusions were deducted from the PLS 642 
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regression model for HLB, with the difference being the negative correlation between log P 643 
and extraction efficiency, which was only present for unionised drugs in the working pH (log 644 
P*union fr interaction, Figure 9). The positive effect of aqueous solubility and its interaction 645 
with log P can be attributed to the more effective elution of polar compounds, when eluted with 646 
MeOH.  647 
3.2.4. Designing a roadmap for effective sample treatment using solid phase extraction 648 
In summary, tC18 and HLB cartridges can be effectively used for drugs of low to 649 
intermediate lipophilicity (log P = 0-5) while for extremely hydrophilic compounds, the use of 650 
C8 cartridge and the omission of the washing step (where possible) were the most effective 651 
options (Figure 10). In the whole range of compounds, it was shown that both HLB and tC18 652 
cartridges can be used, with HLB being more efficient for highly soluble drugs and also for 653 
weak acids, which are fully unionised at the working pH. Therefore, for highly soluble or 654 
weakly acidic compounds with a log P value between 0 and 5 the use of HLB cartridges is 655 
suggested. For drugs of extreme lipophilicity (log P > 5), increasing the strength of the elution 656 
solvent to 100% organic content usually increased the amount of drug recovered, but in certain 657 
cases recovery did not exceed 10-20% despite the attempted modifications of the initial 658 
protocol. Taking that into consideration, we suggest the use of 100% MeOH as elution solvent 659 
for compounds of extreme lipophilicity (using either one of the cartridges). HLB is suggested 660 
as the SPE cartridge of choice for the same reason as in compounds of moderate lipophilicity. 661 
For extremely lipophilic compounds (log P < 0), alternative cartridges could possibly be used 662 
(e.g. C8) for maximum efficiency, and if the medium permits, the washing step after sample 663 
loading in order could be omitted so as to maximise the amount of compound still retained on 664 
the cartridge before the elution step. Due to the high variability and poor recovery results 665 
obtained for many of the drugs across the range of lipophilicity studied, we have concluded 666 
that solid phase extraction, used as is, without a prior purification step is not an adequately 667 
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robust technique for sample clean-up. We suggest the use of a correction factor by using at 668 
least a triplicate for each standard in FeSSGF across the range of concentrations used in 669 
biorelevant dissolution and solubility studies in order to account for the high method 670 
variability.  671 
4. Conclusion 672 
Prediction of gastric food effect on drug absorption has been a big challenge for the 673 
pharmaceutical industry. Even though the in vivo properties of the fed state gastric environment 674 
have been quite well determined and some progress has been made with the development of 675 
gastric biorelevant media, a universal robust predictive analytical method has not been yet 676 
developed. The utility of such a method will allow the effective extraction and drug 677 
quantification of a range of drugs in heterogeneous fed biorelevant media selected on the basis 678 
of properties related to the medium, active ingredient or both. The above would drive drug 679 
analysis towards more standardised protocols and away from the current drug-by-drug 680 
assessment for optimal treatment conditions. The current study assessed the effective 681 
quantification of drugs, based on their physicochemical properties from milk-based media 682 
using two extraction techniques: i. Protein precipitation and ii. Solid phase extraction. The 683 
current study demonstrated that the use of three precipitation reagents (methanol, acetonitrile 684 
and 10% w/v trichloroacetic acid) at a FeSSGF:reagent ratio of 1:2, when used according to 685 
the guidelines proposed, provided a simple sample preparation method which can be decided 686 
based on drugs’ selected physicochemical properties. 10 % w/v trichloroacetic acid was mostly 687 
suitable for weak bases of log P < 2, while either methanol or acetonitrile were effective for all 688 
the other model drugs. It has also been shown that the solid phase extraction protocols proposed 689 
using three different cartridges (tC18, C8 and HLB) provided good sample treatment methods 690 
for all drugs of a wide range of log P values (0.30–4) achieving recovery values > 69.5%. 691 
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Modifications of the initial protocols, involving cartridge treatment and different elution 692 
solvents, improved the % recovery of the extremely lipophilic and extremely hydrophilic model 693 
drugs (9-60%), but with results still indicating that solid phase extraction is possibly not the 694 
method of choice for drugs of higher lipophilicity. Knowledge of the drug’s key 695 
physicochemical properties is critical for the selection of the optimum extraction protocol for 696 
milk-based fed state media. In this study, the effect of the drug’s physicochemical properties 697 
(lipophilicity, ionisation, aqueous solubility, protein affinity) and their interactions on recovery 698 
efficiency from fed state media were assessed, allowing the selection of the optimum extraction 699 
tool for drug quantitative analysis. The roadmaps developed for the two extraction techniques, 700 
can provide a starting point towards the development of a unified guideline, where selection of 701 
the extraction method can be made on the drug physicochemical profile, where drug 702 
physicochemical properties may be used to estimate the approximate % recovery in a specific 703 
extraction. It is evident though that the findings of the current study have been based on the 704 
effect of the physicochemical properties of the drug substance and may not always be directly 705 
applicable in the analysis of formulations, where drug-excipient or medium-excipient 706 
interactions may take place. Further studies are required for the elucidation of the analytical 707 
profile of a range of compounds in heterogeneous biorelevant media simulating the gastric fed 708 
state, while the effect of excipients in drug analysis needs to be assessed in order to determine 709 
the method’s applicability in biorelevant dissolution studies.710 
 711 
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Tables 989 
Table 1 Physicochemical properties and working concentrations of model compounds.  990 
Drug 
log aqueous solubility  
(mg/ mL) [25-29] 
log P  
[26, 28-41] 
pKa  
[28, 39, 42-50] 
Working 
concentrations 
(μg/ mL) (d) 
Plasma protein 
bound (b) 
Metformin hydrochloride 2.48 -0.56 12.40 2000/2 0.035 
Atenolol 1.11 (a) 0.23 9.60 200 0.129 
Paracetamol 1.24 (a) 0.30 9.50 200 0.124 
Furosemide -1 (b) 0.74 3.90 80/1 0.031 
Metoprolol tartrate 1.01 1.95 9.70 200/10 0.244 
Pravastatin sodium -0.42 (b) 2.20 4.36 40 0.767 
Nifedipine -1.90 2.91 3.93 60/1 0.999 
Propafenone hydrochloride -0.82 (b) 3.39 9.27 600 0.957 
Celecoxib -2.52 (b) 3.47 11.10 100 0.975 
Ketoconazole -2.57 (a) 3.72 3.25, 6.22 150 0.986 
MK-C1 -2.53 (c) 4 (c) 6.5 (c) 35 0.908 
Azithromycin 3 (a) 4.02 8.74, 9.45 1000 0.558 
 46 
Danazol -3 4.20 none (b) 25/1 0.983 
Atorvastatin calcium -2.59 (a) 4.22 4.46 160 0.178 
Atovaquone -3.37 5.07 5.01 (b) 25 0.995 
MK-C2 -3 (c) 5.11 (b) 4.48, 5.74 (c) 1300 0.985 
Itraconazole -6 6.20 3.70 0.5/0.1 0.997 
Lapatinib -5.68 (a) 6.30 (a) 6.34 (a) 8.7 0.998 
MK-C3 insoluble (c) 6.31 (b) 3.53 (c) 500 0.997 
MK-C4 -4 (c) 8.81 (c) none (c) 4.5 0.999 
 991 
(a) Sci-Finder  992 
(b) Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2016 ACD/Labs) 993 
(c) Data provided by Merck and Co, INC 994 
(d) “High” concentration/“Low” concentration. “High” concentration = 
𝑑𝑟𝑢𝑔 𝑑𝑜𝑠𝑒 (𝑚𝑔)
500 (𝑚𝐿)(𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑦𝑝𝑖𝑐𝑎𝑙𝑙𝑦 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑔𝑎𝑠𝑡𝑟𝑖𝑐 𝑓𝑒𝑑 𝑑𝑖𝑠𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑠𝑡𝑢𝑑𝑖𝑒𝑠)
 or solubility 995 
in mik/FeSSGF (literature values) or performed solubility study (24 h) in FeSSGF. “Low” concentration = 10 x LOQ in acetate buffer, MeOH:buffer 996 
(1:1) or ΑCN:buffer (1:1) and ≤ 0.2 x “high” concentration. Otherwise, 0.2 x “high” concentration was selected. 997 
  998 
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Table 2 HPLC methods (or modification of published methods) used for the quantification of the model compounds. 999 
Drug Column Mobile phase 
Flow rate 
(mL/min) 
Temperature 
(° C) 
Inj. volume 
(μL) 
UV detection 
(nm) 
Nifedipine  
[53] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:H2O 
60:40  
1 20 50 238 
Furosemide  
[54] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:Formic acid 0.1% v/v  
60:40 
0.8 25 20 233 
Metoprolol tartrate  
[55] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:TFA 0.1% v/v  
47:53 
0.8 10 50 274 
Danazol 
[56] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:H2O  
85:15 
1 25 100 285 
Metformin 
hydrochloride  
[57] 
Vydac Diphenyl, 300Å, 
250 x 4.6 mm, 5 μm 
ΑCN:Phosphate buffer 0.02 
M 
(pH = 7) 70:30 
1 20 20 236 
Itraconazole  
[58] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:H2O 80:20 1 35 100 260 
Celecoxib 
[59] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:H2O  
70:30 
0.8 25 100 251 
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Atovaquone  
[60] 
Waters Spherisorb S5 
ODS2, C18, 80Å, 250 x 
4.6 mm, 5 μm 
ΑCN:TFA 0.4% v/v 
70:30 
1.5 25 50 253 
Paracetamol  
[61] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:H2O 20:80 1 10 20 257 
Ketoconazole  
[62] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:H2O:DEA  
75:25:0.1 
1 25 50 260 
Atenolol  
[63] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
MeOH:Phosphate buffer 0.01 
M  
(pH = 4.5) 20:80 
1 25 50 240 
Azithromycin  
[64] 
Waters Symmetry C8, 
100Å, 250 x 4.6 mm, 5 
μm 
MeOH:Phosphate buffer 
0.3 M(pH = 7.5) 20:80 
1.2 40 100 210 
Pravastatin sodium  
[65] 
Agilent Eclipse XDB 
C18, 120Å, 250 x 4.6 
mm, 5 μm 
MeOH:Phosphate buffer 
0.03 M (pH = 7) 55:45 
1 25 100 238 
Lapatinib  
[66] 
Agilent EC-C18 
Poroshell, 150 x 4.6 
mm, 2.7 μm 
ΑCN:Ammonium acetate 
0.05 M  
(pH = 4.5) 
Gradient (0-5 min 40:60/ 5-
13 min 58:42/ 13-17 min 
90:10/ 17-19 min 40:60) 
0.9 40 50 261 
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Propafenone 
hydrochloride  
[67] 
Agilent Eclipse XDB 
C18, 120Å, 250 x 4.6 
mm, 5 μm 
MeOH:ΑCN:TEA: 
H2O  
50:7.5:0.1: q.s 100 (pH= 2.9)  
0.8 25 20 248 
Atorvastatin calcium  
[68] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 μm 
ΑCN:Phosphate buffer 0.025 
M  
(pH = 6) 40:60 
1.5 30 50 246 
MK-C1* 
Waters Symmetry 
Shield C18, 100Å, 50 x 
4.6 mm, 5 μm 
ΑCN:Phosphate buffer 0.025 
M  
(pH = 2.5) 
Gradient (0-2 min 65:35/ 2-
2.01 min 90:10/ 2.01-3 min 
90:10/ 3-3.01 min 65:35) 
3 40 20 214 
MK-C2* 
Phenomenex Onyx 
monolithic C18, 300Å, 
100 x 4.6 mm 
ΑCN: 0.1% H3PO4 70:30 5 40 10 240 
MK-C3* 
Agilent Prorochell C18, 
120 Å, 50 x 2.7 mm 
ΑCN:Sodium Phosphate 
0.005 M  
(pH = 7) 
Gradient (0-0.5 min 40:60/ 3-
3.5 min 10:90/ 3.51-5 min 
40:60 
1 40 25 250 
MK-C4* 
Phenomenex Onyx 
monolithic C18, 300Å, 
100 x 4.6 mm 
ΑCN:H2O 70:30 3.5 40 100 220 
*HPLC methods were provided by Merck and Co, INC.  1000 
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Figure captions 1001 
Figure 1 Protein precipitation reagent-ratio-log P gradient map; contour plot of % recovery 1002 
after protein precipitation of drug solution at “high” concentration in FeSSGF for the six 1003 
compounds of the pilot study. “Warm” colours (red, orange) indicate high recovery values and 1004 
“cold” colours (green, blue) indicate poor reagent performance. Log P values of -0.56, 0.74, 1005 
1.95, 2.91, 4.20, 6.20 correspond to metformin hydrochloride, furosemide, metoprolol tartrate, 1006 
nifedipine, danazol and itraconazole, respectively. 1007 
Figure 2 Three-way ANOVA results of protein precipitation conditions for the six drugs of the 1008 
pilot study. Graphs denote % drug recovery for all reagents at high (blue) and low (green) 1009 
concentrations. The fractions presented in the centre of the Figure denote the FeSSGF:reagent 1010 
ratio used in the protocol (* p < 0.05, ** p < 0.01, *** p < 0.001, Bonferroni post-hoc test).  1011 
Figure 3 Mean % recovery values of the selected protein precipitation reagents (MeOH, ACN, 1012 
10% w/v TCA) for the 20 model drugs (Table 1), a. vs. log P and log aqueous solubility 1013 
(mg/mL), b. vs. log P and pKa, c. vs unionized fraction and log P and d. vs charge vs protein 1014 
bound fraction as 3D scatter plots. 1015 
Figure 4 % recovery variability obtained with the use of the selected protein precipitation 1016 
reagents (MeOH, ACN, 10% w/v TCA) or SPE cartridges (tC18, HLB) for the 20 model drugs 1017 
(Table 1), expressed as % CV. The dashed line represents the acceptable limit proposed for 1018 
mean % recovery. 1019 
Figure 5 Variable importance in the projection (VIP) plot with the variables classed according 1020 
to their importance of the response (left) for the selected protein precipitation protocols. 1021 
Standardised coefficients corresponding to the variables (and their interactions) studied. Green 1022 
colour denotes coefficients of VIP values > 1, which are considered influential to the response 1023 
value (right). 1024 
Figure 6 Roadmap of protein precipitation conditions selected for maximum % drug recovery 1025 
from the fed gastric medium.  1026 
Figure 7 a. % recovery values of model drugs using the SPE protocols for tC18 and HLB 1027 
cartridges. b. % recovery values of model drugs of pilot study using different elution volumes 1028 
(tC18 SPE cartridge). Stars denote significant differences between % recoveries of a. different 1029 
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cartridges and b. elution volumes (b) (* p< 0.05, ** p < 0.01, *** p < 0.001, two-sided t-test). 1030 
The dashed line represents the acceptable limit proposed for mean % recovery.  1031 
Figure 8 % recovery values of model drugs, in cases where the SPE protocols had to be 1032 
modified (< 50% recovery obtained with the initial analytical methodologies) The bar charts 1033 
represent the drugs where modifications of the standard SPE protocols led to improved % 1034 
recovery values. 1035 
Figure 9 Variable importance in the projection (VIP) plot with the variables classed according 1036 
to their importance of the response (left) for the selected SPE protocols. Standardised 1037 
coefficients corresponding to the variables (and their interactions) studied. Green colour 1038 
denotes coefficients of VIP values > 1, which are considered influential to the response value 1039 
(right).  1040 
Figure 10 Roadmap of solid phase extraction conditions selected for maximum % drug 1041 
recovery from the fed gastric medium. 1042 
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